- Home
- SUPN
as 07-26-2024 4:00pm EST
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 1.6B | IPO Year: | 2012 |
| Target Price: | $41.00 | AVG Volume (30 days): | 551.0K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.99 - $35.44 | Next Earning Date: | 08-06-2024 |
| Revenue: | $597,401,000 | Revenue Growth: | -10.64% |
| Revenue Growth (this year): | 0.76% | Revenue Growth (next year): | 4.08% |
Stock Insider Trading Activity of Supernus Pharmaceuticals Inc. (SUPN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Mar 21 '24 | Sell | $35.31 | 14,491 | $511,677.21 | 8,570 | SEC Form 4 |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Mar 20 '24 | Sell | $35.31 | 400 | $14,124.00 | 8,570 | SEC Form 4 |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Mar 19 '24 | Sell | $35.31 | 12,364 | $436,572.84 | 8,570 | SEC Form 4 |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Mar 13 '24 | Sell | $34.10 | 26,250 | $895,125.00 | 8,570 | SEC Form 4 |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Mar 13 '24 | Sell | $33.48 | 36,116 | $1,209,163.68 | 8,570 | SEC Form 4 |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Mar 12 '24 | Sell | $32.99 | 3,884 | $128,133.16 | 8,570 | SEC Form 4 |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Feb 26 '24 | Sell | $30.21 | 5,000 | $151,050.00 | 8,570 | SEC Form 4 |
| Martin Tami Tillotson | SUPN | Sr. V.P., Regulatory Affairs | Jan 10 '24 | Sell | $27.91 | 8,000 | $223,280.00 | 85,664 | SEC Form 4 |
| Hudson Frederick M. | SUPN | Director | Nov 15 '23 | Sell | $28.50 | 3,882 | $110,637.00 | 38,442 | SEC Form 4 |
| Hudson Frederick M. | SUPN | Director | Nov 15 '23 | Sell | $28.50 | 5,211 | $148,513.50 | 33,231 | SEC Form 4 |
Latest Supernus Pharmaceuticals Inc. News
SUPN Breaking Stock News: Dive into SUPN Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
SUPN: Raising target price to $24.00
GlobeNewswire
3 days ago
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
Argus Research
10 days ago
SUPN: Raising target price to $23.00
Argus Research
17 days ago
SUPN: What does Argus have to say about SUPN?
Motley Fool
2 months ago
VanEck Semiconductor ETF Is Riskier Than You Think
Motley Fool
2 months ago
A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?
Reuters
2 months ago
Norway wealth fund to vote against Musk's $56 billion Tesla pay package
Simply Wall St.
2 months ago
Oberstdorfer Bergbahn Reports Full Year 2023 Earnings
Compare SUPN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SUPN Supernus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.